Under a tenth of individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it releases its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just access to these injectable treatments.
According to projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The latest guidelines recognises that obesity is a lifelong illness that can be treated with holistic and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key obstacles to universal access to the treatments that can assist patients in reducing substantial body mass, notes the agency.
Weight-Loss Drug Scarcity
Even in the present most favorable scenario, the manufacturing of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The advice encourages countries and companies to expand availability, by strategies including licensing agreements.
The intellectual property rights on a key compound – the main ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Drugs Work
These medications imitate a natural hormone to reduce digestion speed, curb appetite and boost the sense of being full so individuals eat less.
People commonly see weight reduction within a few weeks of beginning the regular doses.
Studies points to patients may put most of the weight back on within a year of stopping the medication, when their usual appetite resume.
Being above a healthy weight raises your chance for developing medical conditions, like diabetes, heart disease, brain attack, and specific malignancies.
Excess weight concerns people in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the health agency.
